- Multi-national epigenetics company, VolitionRx (NYSE:VNRX) appointed Dr Andrew Retter as its chief medical officer, effective April 1, 2024.
- Andrew is an Intensive Care Consultant at Guy’s and St. Thomas’ NHS Foundation Trust in London, where he has worked as a Consultant since 2014 and leads Clinical Governance in Critical Care.
